Curriculum Vitae

Daniel D. Esmaili, M.D.

June 2018

BUSINESS ADDRESS: Retina Vitreous Associates Medical Group

1245 Wilshire Blvd., Suite 380
Los Angeles, CA 90017
(213) 483-8810 Telephone
(213) 481-1503 FAX

9001 Wilshire Blvd. Suite 301
Beverly Hills, CA 90211
(310) 854-6201 Telephone
(310) 652-7520 FAX

12840 Riverside Drive, Suite 333
North Hollywood, CA 91607
(818) 754-2090 Telephone
(818) 508-9420 FAX

3440 Lomita Blvd. Suite 327
Torrance, CA 90505
(310) 891-1000 Telephone
(310) 891-1003 FAX

301 S. Fair Oaks Blvd. Suite 301
Pasadena, CA 91105
(626) 204-1410 Telephone
(626) 204-1420 FAX

5525 Etiwanda Ave., Suite 112
Tarzana, CA 91356
(818) 578-7408 Telephone
(818) 578-7409 FAX

PRESENT POSITION Partner

START DATE April 2014

COLLEGE:
University of California at Los Angeles
Los Angeles, California
Bachelor of Science, Physiological Sciences
1994-1998

MEDICAL SCHOOL:
University of Southern California Keck School of Medicine
Los Angeles, California
Doctor of Medicine
1999-2003

INTERNSHIP:
Scripps Mercy Hospital
San Diego, California
Transitional Intern
2003-2004

RESIDENCY:
Doheny Eye Institute
University of Southern California Keck School of Medicine
Los Angeles, California
Resident in Ophthalmology
2004-2007

FELLOWSHIP:
Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston, Massachusetts
Vitreoretinal Fellow
2007-2008

Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston, Massachusetts
Chief Vitreoretinal Fellow
2008-2009

BOARD CERTIFICATION:
Medical Board of California, 2005-present
Medical Board of Massachusetts, 2007-2014
Medical Board of Rhode Island, 2009-20012
Diplomate, American Board of Ophthalmology,2009-present

PROFESSIONAL BACKGROUND:

Retina Vitreous Associates Medical Group
Partner
Los Angeles, CA
April 2014-present

Retina Consultants of California, Inc.
Associate
Glendale, California
July 2013-February 2014

Instructor in Ophthalmology (Full-time faculty)
Medical Director, MEEI satellite office (Stoneham, MA)
Retina Service, Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston, Massachusetts
July 2012-June 2013

Clinical Instructor in Ophthalmology
Retina Service, Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston, Massachusetts
(Research, clinical care, supervise vitreoretinal fellows)
July 2009-June 2012

Retina Consultants, Inc.
Associate
Providence, Rhode Island
(Provided clinical care 4 days/week in a private setting while also serving as retina faculty for the Brown Dept. of Ophthalmology)
September 2009-June 2012

SOCIETY MEMBERSHIPS:

1 - Fellow, American Academy of Ophthalmology
2 - Alpha Omega Alpha Honor Medical Society
3 - Society of Heed Fellows
4 - Pan American Association of Ophthalmology
5 - American Society of Retina Specialists
6 - Massachusetts Society of Eye Physicians and Surgeons

SPECIAL HONORS:

- Cum Laude, University of California *at Los Angeles*, 1998
- Departmental Honors, University of California at Los Angeles, 1998
- Baxter Fellowship, USC Keck School of Medicine*,*2000
- Douglas and Jean Bailey Award, USC Keck School of Medicine, 2001
- Excellence in Research Award, Western Medical Student Research *Forum*, 2001
- Hoffman Scholarship, USC Medical Student Research Forum, 2001

- Eric Cohen Clinical Medicine Award (Finalist). USC Keck School of Medicine, 2002
- Recognition of Excellence, Assoc. of Professors and Scholars of Iranian Heritage, 2003
- Graduate and Professional Recognition Award, USC (main campus), 2003
- Dean's Scholar. USC Keck School of Medicine, 2003
- American Medical Association Research Award; for the top student in the class of 2003 who authored a meritorious research paper, 2003
- American Medical Association Clinical Award; for most outstanding academic achievement in the third year of medical school, 2003
- Medical School Honors - Graduation with Highest Distinction, USC Keck School of Medicine; top 6% of graduating class for academic performance, 2003
- Alpha Omega Alpha Honor Medical Society, elected member, 2003
- Chief Vitreoretinal Fellow, Massachusetts Eye and Ear Infirmary, 2008
- Paul Kayser International Scholar, Pan-American Ophthalmological Foundation,2008
- Heed Fellowship, Heed Ophthalmic Foundation,2008
- Super Doctors Southern California, Rising Stars 2015
- Super Doctors Southern California, Rising Stars 2016
- Top Doctors, Pasadena Magazine, 2016
- Super Doctors Southern California, Rising Stars 2017

ACEDEMIC AFFILIATION:

- Clinical Instructor in Ophthalmology. Harvard Medical School, 2009-6/2012
- Adjunct Instructor of Surgery. Brown Alpert School of Medicine, 2010-6/2012
- Clinical Associate. Massachusetts General Hospital, 7/2012- 6/2013
- Instructor in Ophthalmology. Mass Eye and Ear/Harvard 7/2012- 6/2013
- Medical Director. Mass Eye and Ear Retina Consultants, Mass Eye and Ear/Harvard Medical School, 7/2012- 6/2013
- Volunteer Faculty. Los Angeles County – University of Southern California, 2017

TEACHING APPOINTMENTS:

Medical Scholars Program, Instructor for Gross Anatomy course. USC, 2000-2001

Research Preceptor, Mass Eye and Ear. *Supervised Andrea* Giani, MD during his research fellowship in retinal imaging. 2009-2011

Preceptor, Brown Alpert School of Medicine, Dept. Ophthalmology. Supervised resident retina clinic *(1 session/week;* 3 months/year) and staffed retina surgical cases. 9/2009-6/2012

Harvard Vitrectomy Course, Massachusetts Eye and Ear Infirmary, 2011

Harvard Vitrectomy Course, Massachusetts Eye and Ear Infirmary, 2012

Panel discussant. Second International Biennial Symposium on AMD. Boston, MA. Imaging section, Sept 21-22, 2012

Moderator. AAO Retina Subspecialty Day. Chicago, IL. Imaging section, Nov 15-16, 2012

Clinical Preceptor, Mass Eye and Ear. *Clinical and surgical* preceptor for vitreo-retinal fellows and ophthalmology residents.
7/2012 – 6/2013

COMMITTEE SERVICE:

Curriculum Committee, *Representative. USC,* 1999-2001
Admissions Committee, *Interviewer. USC,* 2000-2001
Medical Student Research Committee, *Representative. USC,* 2000-2002
Board of Councilors, *Member-in-training Representative,* 2006-2007
California Academy of Eye Physicians and Surgeons 2009
Fellowship Committee, *Massachusetts Eye and Ear Infirmary*, 2008-2009
AAO Ambassadors Program, *sponsored by The Macula Society*2008-2009

EDITORIAL ACTIVITIES:

Reviewer, Digital Journal of Ophthalmology, 2007
Reviewer, Investigative Ophthalmology and Visual Science, 2013

PUBLICATIONS:

1. **Esmaili DD,** Arnold A.
"Testosterone did not further masculinize HVC and RA nuclei of estradiol-treated female Zebra Finches."
Honors Thesis. Advisor: Arthur Arnold, Ph.D. Department of Physiological Sciences, University of California Los Angeles. 1998

2. Perng GC, Slanina SM, Yukht A, Osorio N, **Esmaili DD**, Ghiasi H, Nesburn AB, Wechsler SL.
"Multiple regions of LAT are involved in HSV-1 spontaneous reactivation in the rabbit."
The 24th International Herpesvirus Workshop, 1999. Boston, Massachusetts

3. Perng GC, **Esmaili DD**, Slanina SM, Yukht A, Ghiasi H, Osorio N, Maguen B, Nesburn AB, Wechsler SL.
"Two HSV-1 LAT mutants: one with increased virulence in mice but not rabbits and one with increased virulence in rabbits but not mice."
The 25th International Herpesvirus Workshop, 2000. Portland, Oregon

4. **Esmaili DD**, Nesburn AB, Wechsler SL, Perng GC.
"Herpes simplex type 1 LAT mutant demonstrates decreased spontaneous reactivation with wild type neurovirulence and corneal disease phenotype."
Journal of Investigative Medicine. 2000;49,1:258.

5. Perng GC, **Esmaili D**, Slanina SM, Yukht A, Ghiasi H, Osorio N, Mott KR, Maguen B, Jin L, Nesburn AB, Wechsler SL.
"Three herpes simplex virus type 1 latency-associated transcript mutants with distinct and asymmetric effects on virulence in mice compared with rabbits."

PUBLICATIONS (continued):

Journal of Virology. 2001;75(19):9018-28

6. **Esmaili DD**, Shubin R, Waters CH, Sadun AA.
"Eye movement abnormalities in a case of X-linked dystonia-parkinsonism (lubag)."
J of Neuroophthalmol. 2004;24(2):188-9

7. **DD Esmaili**, KA Tawansy, MK Russell, and S Ianchulev.
"Delayed lensectomy with intra–ocular lens implantation in eyes with ROP retinal detachment."
Invest. Ophthalmol Vis Sci. 2005;46:4091 (ARVO)

8. **DD Esmaili**, Z Wu, RF See, AL Murphree, and JI Lim.
"Comparison of clinical and ultrasonographic characteristics of intraocular melanoma in younger vs. older patient populations."
Invest. Ophthalmol Vis Sci. 2006;47:2255 (ARVO)

9. O'Hearn TM, Fawzi A, **Esmaili D**, Javaheri J, Rao NA, Lim JI.
"Presumed ocular tuberculosis presenting as a branch retinal vein occlusion in the absence of retinal vasculitis or uveitis."
Br J Ophthalmol. 2007;91(7):981-2.

10. **Daniel D. Esmaili MD**, Roya H. Ghafouri MD, Usha Chakravarthy MD, Jennifer I. Lim MD.
"Quantitative Retinal Imaging, in Lim JI (ed)"
Age-Related Macular Degeneration, 2nd edition. Taylor and Francis, New York. 2007

11**. DD Esmaili**, Sadda SR Walsh AC.
"Quantitative optical coherence tomography analysis of choroidal neovascular membranes following photodynamic therapy."
Invest. Ophthalmol. Vis Sci. 2007;48:2608 (ARVO)

12. de Bruin DM, Burnes DL, Loewenstein J, Chen Y, Chang S, Chen T, **Esmaili DD**, de Boer JF.
"In-vivo three-dimensional imaging of neovascular age related macular degeneration using optical frequency domain imaging at 1050 nm."
Invest Ophthalmol Vis Sci. 2008;49(10):4545-52

13. **Esmaili DD**, O'Hearn TM, Chang EL, Smith RE, Rao NA.
"Simultaneous presentation of kimura's disease and angiolymphoid hyperplasia with eosinophilia."
Ophthal Plast Reconstr Surg. 2008;24(4):310-1.

14. **DD Esmaili**, DM de Bruin, D Burnes, Y Chen, S Chang, T Chen, JF de Boer, J Loewenstein.
"Optical frequency domain imaging of type I choroidal neovascular membranes in age related macular degeneration patients treated with ranibizumab."
Invest. Ophthalmol Vis Sci. 2008;49:900 (ARVO)

15. D Burnes, DM de Bruin, J Loewenstein, Y Chen, S Chang, T Chen, **DD Esmaili**, JF de Boer.
"*In-vivo* 3D imaging of age related macular degeneration using optical coherence tomography at

PUBLICATIONS (continued):

1050 nm."
Invest. Ophthalmol Vis Sci. 2008;49:5392 (ARVO)

16. **Esmaili DD**, Mukai S, Kim IK, Jakobiec FA, Gragoudas ES.
"Ocular melanocytoma."
Int Ophthalmol Clin. 2009;49(1):165-75

17. **Esmaili DD**.
"New horizons for anti-VEGF therapy."
The Ophthalmology Report. Selected reports from the 26th annual meeting of the American Society of Retina Specialists. 2009;2(2):5-8.

18. **Esmaili DD,** Miller JW.
"Practice patterns: Exudative age-related macular degeneration."
Retina Times. 2009, Issue 31, Vol 27, No.4.

19. **Esmaili DD**, Giani A, Vavvas D, Andreoli CM, Delori FC, Miller JW.
"Fundus autofluorescence imaging of choroidal neovascular membranes."
Retina Congress, 2009. New York, New York.

20. Giani A, Cigada M, **Esmaili DD,** Salvetti P, Luccarelli S, Marziani E, Luiselli C, Sabella P, Cereda M, Eandi C, Staurenghi G.
"Artifacts in automatic retinal segmentation using different optical coherence tomography instruments."
Retina. 2010;30(4):607-16

21. Chen L, Wang K, **Esmaili DD**, Xu G.
"Rhegmatogenous retinal detachment due to paravascular linear retinal breaks over patchy chorioretinal atrophy in pathologic myopia."
Arch Ophthalmol. 2010;128:1551-4.

22. **Esmaili DD,** Loewenstein JI.
"Retinal artery occlusion. Focal Points, clinical modules for ophthalmologists."
American Academy of Ophthalmology. March, 2010.

23. Choudhry N, Giani A, **Esmaili DD**, Deiro P, Staurenghi G, Miller JW.
"Choroidal thickness in geographic atrophy using enhanced depth imaging."
Invest. Ophthalmol Vis Sci. 2010;1013/A576. (ARVO)

24. Giani A, **Esmaili DD**, Luiselli C, Pellegrini M, Invernizzi A, Cigada M, Miller JW, Staurenghi G.
"Displayed reflectivity of choroidal neovascular membranes by optical coherence tomography correlates with presence of leakage by fluorescein angiography."
Retina. 2011;31(5):942-8

25. Giani A, Luiselli C, **Esmaili DD**, Solvetti P, Cigada M, Miller JW, Staurenghi G
"Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization."

PUBLICATIONS (continued):

Invest Ophthal Vis Sci. 2011;52(8):5579-86

26. **Esmaili DD**.
"Valved Cannula Systems."
Retina Today. May/June, 2012.

27. **Esmaili DD**, Boyer DS.
"Treatment of DME beyond anti-VEGF"
Retinal Physician. January 2015.

28. Tabandeh H, Dayani PN, **Esmaili DD**, Boyer DS. "Wide-angle fundus fluorescein angiography in eyes with clinically stable proliferative diabetic retinopathy"
33d annual meeting of the American Society of Retina Specialists (ASRS). Vienna, Austria. July 2015.

29. **Esmaili DD**, Boyer DS.
"Drug Delivery to the Posterior Segment"
Retina Today. September 2015.

30. **Esmaili DD.**
"Chorioretinal atrophy in alagille syndrome"
Retina Cases and Brief Reports. 2015 Fall;9(4):330-2

31. Munk MR, Jampol LM, Souza EC, Andrade G, **Esmaili DD**, Sarraf D, Fawzi AA.
"New associations of classic acute macular neuroretinopathy"
British Journal of Ophthalmology. 2016;100(3):389-94

32. Thanos A, **Esmaili DD**, Eliott D.
"Cotton wool spots; not that innocent"
JAMA Ophthalmology. 2015;133(12):1471-2

33. Thanos D. Papakostas, MD, Laurence Lim, MD Tave van Zyl, MD, John B. Miller, MD, Bobeck S. Modjtahedi, MD, Christopher M. Andreoli, MD, David Wu, MD, PhD, Lucy H. Young, MD, PhD, Ivana K. Kim, MD, Demetrios G. Vavvas, MD, PhD, **Dan D. Esmaili**, MD, Deeba Husain, MD, Dean Eliott, MD and Leo A. Kim MD, PhD
"Intravitreal Aflibercept for macular edema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab"
33d annual meeting of the American Society of Retina Specialists (ASRS). Vienna, Austria. July 2015

34. Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM, Wu D, Young LH, Kim IK, Vavvas DG, **Esmaili DD**, Husain D, Eliott D, Kim LA.
"Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab"
Eye. 2016;30(1):79-84

35. Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network.

"Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema"
JAMA Ophthalmol. 2016 Feb;134(2):127-34

36. **Esmaili DD.**
"Iatrogenic occlusion of the ophthalmic artery after sodium tetradecyl sulfate injection in the forehead"
Retina Cases and Brief Reports. 2017 Winter;11, Suppl 1

37. **Esmaili DD**, Boyer DS. Recent advances in understanding and managing retinal vein occlusions. F1000Res. 2018 Apr 16;7:467

RESEARCH ACTIVITIES:

Principal Investigator
Apellis APL2-203 – A Phase 1b/2 Multi-center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 therapy in Patients with Neovascular Age-Related Macular Degeneration

Sub-Investigator
Opthea OPT-302-1002- A Dose-Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, compared with Ranibizumab Alone in participants with Treatment Naïve Neovascular Age-Related Macular Degeneration

Sub-Investigator
Adverum ADVM-022-02- An Open Label Dose-escalation Study to Evlauate the Safety and Tolerability of a Single Intravitreal Injection of ADVM-022 in Subjects with Neovascular Age-Related Macular Degeneration

Sub-Investigator
Santen DE-122 Protocol 36-002- A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy, Safety of Intravitreal Injections of De-122 in combination with Lucentis compared to Lucentis Monotherapy in Subjects with Wet Age-related Macular Degeneration

Sub-Investigator
Novartis Kestrel- A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizuma versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema

Sub-Investigator
Novartis- A randomized, active-controlled, subject and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema

RESEARCH ACTIVITIES (continued):

Sub-Investigator
Kodiak KSI-301- A Phase I Open Label, Multi-center Study to Investigate Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following a Single Intravitreal Administration of KSI-301 in Subjects with Center Involved Diabetic Macular Edema

Sub-Investigator
ROCHE GR40349- A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO 686741 in Patients with Diabetic Macular Edema

Sub-Investigator
Opthea OPT-302-1003- A Two Part Multicenter Evaluating OPT-302 in Combination with Aflibercept, Consisting of a Phase 1b Open-label, Sequential Dose Escalation Study Followed by Phase 2a Randomized, Double Masked, Dose Expansion Stud

Sub-Investigator
Clearside Topaz- A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLs-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with RVO

Sub-Investigator
Graybug-GBV-102-001- A Phase ½ Multicenter Study Evaluation the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-Related Macular Degeneration

Sub-Investigator
Robin 1386.2- A Randomized, Double-masked, Placebo Controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered 10mg BI 1467335 for 12 weeks with a 12 week follow-up period in patients with NPDR without Center-involved DME

Sub-Investigator
Allegro – A randomized, Controlled, Double-Masked, Crossover Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Intravitreal Injection of 1.0 mg Luminate (ALG-1001) VS. SHAM as a treatment for Non-Exudative Macular Degeneration

Sub-Investigator
Kalvista- A Randomized Sham-Controlled Double-Masked Phase 2a Study of the Efficacy, Safety and tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema who have had prior Anti-VEGF Treatment

Sub-Investigator
OPH2007 – A Phase 2A Open-Label Trial to Assess the Safety of Zimura (ANTI-C5) Administered in Combination with Lucentis 0.5mg in Treatment Naïve Subjects with Neovascular Age-Related Macular Degeneration

RESEARCH ACTIVITIES (continued):

Sub-Investigator
Aldeyra-ADX-102 – A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects with Non-infectious Anterior Uveitis

Sub-Investigator
ACTHAR – An Open-label, Multi-center, Randomized, Phase II Study of the Safety, and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients with Non-infection Uveitis

Sub-Investigator
Apellis Derby APL2-303 – A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Sub-Investigator
Apellis Oaks APL2-304 – A Phase III, Multi-Center, Randomized, Double-Masked, Sham-controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Sub-Investigator
CellCure (Cohort 4)- OpRegen CCN_CT02- Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry –Form AMD Geographic Atrophy

Sub-Investigator
IMT-PAS-01- Post-approval Study of Implantable Miniature Telescope

Sub-Investigator
Panorama VGFTe-OD-1411 – A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

Sub-Investigator
4D Molecular Therapeutics 4D-CHM-001-NH-0001 – A Multicenter Prospective Observational “Natural History” Study in Patients with Choroideremia

Sub-Investigator
Allergan 150998-012 – Evaluation of Safety and Systemic Pharmacokinetics after Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients with Neovascular Age-Related Macular Degeneration

Sub-Investigator
Omaspect GX30191 – A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy **RESEARCH ACTIVITIES (continued):**

RESEARCH ACTIVITIES (continued):

Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study

Sub-Investigator
Quark QRK207 – A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy

Sub-Investigator
PRO-CON VGFTe-AMD-1507 – A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as PROphylaxis against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes

Sub-Investigator
Clearside Sapphire CLS1003-301 – A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Conjunction with Intravitreal Aflibercept in Subjects with Retinal Vein Occlusion

Sub-Investigator
TLC TLC399A2002 – A Phase IIa Trial of TLC399 (ProDex) in Subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A Double-Masked, Randomized Trial to Evaluate Efficacy and Tolerability

Sub-Investigator
RPT-14-01 – A Phase I/IIA Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (RPE) Cells Seeded on a Polymeric Substrate) in Subjects with Advanced, Dry Age-Related Macular Degeneration (AMD)

Sub-Investigator
Clearside PEACHTREE CLS1001-301 – A Phase 3, RandomizEd, MAsked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for tHe TReatment of Subjects with Macular Edema associated with Non-Infectious UvEitis

Sub-Investigator
Regeneron R910-3-AMD-1517 – A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration

Sub-Investigator
Regeneron R910-3-DME-1518 – A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema

RESEARCH ACTIVITIES (continued):

Sub-Investigator
SciFluor SF0116-C-001 – A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0116 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (DME)

Sub-Investigator
jCyte JC-01E – An Extension Study of JC-01 Evaluating Long-Term Safety of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa (RP)

Sub-Investigator
jCyte JC-02 – A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa (RP)

Sub-Investigator
Roche Chroma GX29176 – A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration

Sub-Investigator
Roche Avenue BP29647 – A Multiple-Center, Multiple-Dose And Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study To Investigate The Safety, Tolerabilty, Pharmacokinetics, And Efficacy Of RO6867461 Administered Intravitreally In Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Sub-Investigator
Allegro DME 202B – A Phase 2 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial Designed to Evaluate The Safety And Exploratory Efficacy of Luminate (ALG-1001) As Compared To Avastin And Focal Laser Photocoagulation In The Treatment Of Diabetic Macular Edema

Sub-Investigator
OPH1006 – Effect of Anti-VEGF Agents Administered On A Quarterly Maintenance Regimen In Subjects With Neovascular AMD Receiving Anti-PDGF Therapy: An 18 Month Phase 2A Open Label, Randomized Study Of Avastin, Lucentis, Or Eylea (Anti-VEGF Therapy) Administered In Combination with Fovista (Anti-PDGF BB Pegylated Aptamer)

Sub-Investigator
Iconic – A Phase 2 Randomized, Double-Masked, Multicenter, Active-Controlled Study Evaluating Administration Of Repeated Intravitreal Doses Of hI-con1 In Patients With Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

RESEARCH ACTIVITIES (continued):

Sub-Investigator
OHR Pharmaceuticals: Phase 2 study of safety, functional and anatomical effect of Squalamine Lactate Ophthalmic Solution 0.2% administered twice daily in subjects with neovascular age related macular degeneration.

Sub-Investigator
Tyrogenex Apex: A Randomized, Double-Masked, Placebo-controlled, Dose-Finding, Non-Inferiority Study of X-82 plus Eylea compared to prn Eylea monotherapy in neovascular AMD.

Sub-Investigator
DRCR Protocol U: Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy

Sub-Investigator
StemCells, Inc. Radiant CL-AMD-201: A Phase II Proof-of-Concept Study of the Safety and Efficacy of HuCNS-SC Subretinal Transplantation in Subjects with Geographic Atrophy of Age-Related Macular Degeneration

Sub-Investigator
Opthea OPT-302-1001: A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in combination with Ranibizumab in subjects with wet AMD

Sub-Investigator
jCyte, Inc JC-01: A Prospective, Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of a Single Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa (RP)

Sub-Investigator
The Endurance 3 Trial: Long-Term Efficacy and Safety of Afibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial. (Phase IV)

Sub-Investigator
Acucela Seattle - A Phase 2b/3 Multicenter, Randomized, Double-Masked, Does-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration

Sub-Investigator
Astellas VIDI 8232-CL-3001- A Phase 2, Double Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema

RESEARCH ACTIVITIES (continued):

Sub-Investigator
Eyeguard A X05230/CL3-78989-005 – A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis

Sub-Investigator
Eyeguard C X05231/CL3-78989-006 – A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment

Sub-Investigator
Eyeguard E X05232 – An Open-Label, Non-randomized, Single-Arm, Roll-Over Study to Continue Dosing of Gevokizumab in Non-Infection Intermediate, Posterior, or Pan-Uveitis Patients Who Each Successfully Completed either the X052130 or the X052131 Study

Sub-Investigator
Psivida PSV-FAI-001 – A Phase III, Multi-Center, Ransomized, Masked, Controlled, Safety and Efficacy Study Of A Fluocinolone Acetonide Intravitreal (FAI) Insert In Subjects With Chronic Non-Infectious Uveitis Affecting The Posterior Segment Of The Eye

Sub-Investigator
Regeneron Capella R2176-3-AMD-1417 – A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study Of The Efficacy And Safety Of Intravitreal Regn2176-3 In Patients With Neovascular Age-Related Macular Degeneration

Sub-Investigator
Neurotech NT-503-3-AMD-001 – A Multi-Center, Two-Stage, Open-Label Phase 1 and Randomized, Active, Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Sub-Investigator
Regeneron R2176-3-AMD-1303 – An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration

Sub-Investigator
ASAP II POT-CP043014 – Assessment of Safety, Tolerablilty and Pharmacokinetics of Intravitreal APL-2 Therapy for Patients with Neovascular Age-Related Macular Degeneration (AMD)

RESEARCH ACTIVITIES (continued):

Sub-Investigator
Clearside Tanzanite CLS-1003-201 – Safety and Efficacy of Suprachoroidal CLS-TA in Combination with Intravitreal Aflibercept in Subject with Macular Edema Following Retinal Vein Occlusion

Sub-Investigator
Kal Vista KVD001-001- An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability And Pharmacodynamics of a Novel Plasma Kallikrein Inhibitor Administered By Intravitreal Injection in Subjects with Central Involved Diabetic Macular Edema and Reduced Vision

Sub-Investigator
Novartis GA - A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration.

Sub-Investigator
RiverVision – A Phase 1 Open-Label Safety And Pharmacodynamic Study of RV001, An Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered By Intravenous (IV) Infusion In Patients With Diabetic Macular Edema (DME)

Sub-Investigator
Filly POT-CP121614 - A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study Of Safety, Tolerability And Evidence Of Activity Of Intravitreal APL-2 Therapy In Patients With Geographic Atrophy (GA) Filly

Sub-Investigator
Santen Sakura 03-007 - A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Sub-Investigator
Genentech Mahalo GA: A Multicenter, Open-Label Extension Study to Evaluate The Long-Term Safety and Tolerability of FCFD4514S in Patients with Geographic Atrophy.

Sub-Investigator
Regeneron R910 Wet AMD/DME: An Open-Label, Dose-Escalation Study of the Safety and TOLERABILITY of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients with Either Neovascular AMD or DME.

Sub-Investigator
Daiichi Sankyo DS7080-A-U101 Wet AMD: Phase 1 Dose Escalation and Expansion Study of DS-7080A in Subjects with Neovascular Age-Related Macular Degeneration.

Sub-Investigator
Allergan 150998-3 (CYPRESS) - Evaluation of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-Related Macular Degeneration

RESEARCH ACTIVITIES (continued):

Sub-Investigator
Allergan 150998-4 (PALM) – Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision due to Diabetic Macular Edema

Sub-Investigator
Regeneron Re-View Wet AMD: Rigorous Evaluation of Vision and Safety with Intravitreal Aflibercept Injection Dosed Every 8 Weeks Over 2 Years in Neovascular AMD.

Sub-Investigator
Ophthotech 1005 – Sub-Retinal Fibrosis in Neovascular AMD : A 24 month Phase 2a Open Label Safety Study of Fovista™ (Anti-PDGF-BB pegylated aptamer) Regimen Administered independently or in combination with Anti-VEGF Therapy (AVASTIN® or EYLEA®) during the induction and maintenance phases of therapy.

Sub-Investigator
Ophthotech 1002 - A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration

Sub-Investigator
Pfizer DME - A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study to Compare the Efficacy and Safety of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) with that of Ranibizumab in Adult Subjects with Diabetic Macular Edema

Sub-Investigator
Trex DME - A phase I/II, open label, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.3 mg ranibizumab given monthly compared to a Treat and Extend protocol, with and without laser photocoagulation, in patients with Diabetic Macular Edema

Sub-Investigator
Allergan ECHO - A Restrospective Data Collection Study in Patients Receiving Anti-VEGF Injections for Retinal Vein Occlusion or DME

Sub-Investigator
VMA Resolvine - A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Traction

Sub-Investigator
Allegro VMA 202 - A Safety and Efficacy Study of ALG-1001 in Human Subjects with Symptomatic Focal Vitreomacular Adhesion

Sub-Investigator
Regeneron wet AMD - An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration (AMD)

RESEARCH ACTIVITIES (continued):

Sub-Investigator
Xcovery - A Phase 1/2 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects with Neovascular Age-related Macular Degeneration (AMD)

Sub-Investigator
Santen DART - A phase I/II, Open label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration

Sub-Investigator
Thrombo Orbit - Ocriplasmin Research to Better Inform Treatment

Sub-Investigator
Aerpio (Phase II) - A Phase 2, Randomized, Active-Controlled, Double-Masked, Mult-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema

Sub-Investigator
Orion - Ozurdex vs Ranibizumab vs combination for Central Retinal Vein OcclusioN (ORION)

Sub-Investigator
OZ-2013 - Dexamethasone Intravitreal Implant for Retinal Vein occlusion-Associated Macular Edema After Treatment Failure with Anti-VEGF

Sub-investigator
Allergan: A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema.

Sub-investigator
Genentech: (BRAVO) A phase III, multicenter, randomized, sham-injection controlled study of the efficacy and safety of ranibizumab injection compared to sham in subjects with macular edema secondary to branch retinal vein occlusion. Genentech: (CRUISE) A Phase III, Multicenter, Randomized, Sham-Injection Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared to Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion.

Sub-investigator
Genentech: (RISE) A Phase III, Double-Masked, Multicenter, Randomized, Sham-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus.

RESEARCH ACTIVITIES (continued):

Sub-investigator
Barnes Retina Institute: (CRAVE) Bevacizumab versus Ranibizumab in Treatment of Macular edema from Vein Occlusion.

PERSONAL INTERESTS:

-Photography (website: 500px.com/desmaili)
-Travel
-Athletics